She participates as a Co-investigator, and contributes to the following work packages (WP): WP2, as coordinator of the “Primary Health Care Group of Salamanca for the Study of MBL” for the population-based recruitment of cases -to collect samples and epidemiological and clinical data-, in the harmonization of epidemiological questionnaires, and in facilitating smooth interactions and integration with National (Spanish) DNA Bank, to ensure an adequate storing of biological samples and data; WP3, in designing, developing and validating “next generation flow” (NGF) approaches for the simultaneous identification of both clonal/tumor cells and immune cells in blood (including automated strategies for analysis); and WP4, to describe the inhibitory /activation receptor protein expression profiles of clonal/tumour cells, also by NGF.

Additionally, she also participates in the Coordination and Management of the Project and in WP6 (Data analysis dissemination and exploitation of results).

Professor Dr Julia Almeida (MD, PhD) is a University Professor of the Department of Medicine of the University of Salamanca (USAL). She is also a Senior Research Scientist at Centro de Investigación del Cáncer de Salamanca (IBMCC, USAL/CSIC) and at IBSAL (Instituto de Investigación Biomédica de Salamanca). She has recognized three consecutive periods of 6 years on research work. Her research has focused on the area of Immunology and Cancer, primarily centred upon the identification of potential factors involved in the ontogeny of clonal T and B lymphocytosis. She is a la co-director of relevant papers, in particular the description for the first time that the presence of clonal B lymphocytes circulating in blood with a CLL-like phenotype is a common finding in the general population (Blood 2009 with >100 cites), and that even would be present in practically all subjects of advanced age (Leukemia 2011), as well the description of differential biological characteristics among these cells and those of chronic lymphatic leukaemia likewise possible factors involved in the natural history of the disease.

She has contributed to contributed to numerous competitive research projects, regional, national or international, of which, in recent years, she was the principal investigator in 8. She is also a co-author of two international patents. As a result of her main research activity, framed within “Immunology and Cancer”, she has published 130 scientific articles in international journals, of which 70 are publications of the first quartile, that were cited more than 4000 times and with and H-index of 36 (WOS sept 2017).